Westwood Holdings Group Inc. Raises Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Westwood Holdings Group Inc. increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 18.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 53,102 shares of the company's stock after buying an additional 8,120 shares during the period. Westwood Holdings Group Inc. owned 0.06% of CRISPR Therapeutics worth $2,090,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Intellectus Partners LLC lifted its stake in shares of CRISPR Therapeutics by 3.6% in the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock valued at $281,000 after purchasing an additional 250 shares during the period. Farrow Financial Inc. lifted its position in CRISPR Therapeutics by 1.4% in the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock valued at $777,000 after acquiring an additional 270 shares in the last quarter. Kestra Private Wealth Services LLC boosted its stake in CRISPR Therapeutics by 1.5% during the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock valued at $812,000 after purchasing an additional 310 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in CRISPR Therapeutics by 7.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock valued at $215,000 after purchasing an additional 372 shares during the last quarter. Finally, Horizon Kinetics Asset Management LLC increased its holdings in CRISPR Therapeutics by 4.3% during the 4th quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company's stock worth $420,000 after purchasing an additional 443 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on CRSP shares. Royal Bank of Canada dropped their target price on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a report on Wednesday, February 12th. Stifel Nicolaus dropped their price objective on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a research note on Thursday, February 13th. JMP Securities reaffirmed a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, May 21st. HC Wainwright reiterated a "buy" rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. Finally, The Goldman Sachs Group dropped their price target on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $71.75.

CRISPR Therapeutics Trading Down 1.8%

Shares of CRISPR Therapeutics stock traded down $0.67 on Monday, reaching $36.86. The stock had a trading volume of 1,256,881 shares, compared to its average volume of 1,690,987. The business's 50 day moving average is $37.05 and its two-hundred day moving average is $41.87. The company has a market cap of $3.18 billion, a P/E ratio of -8.43 and a beta of 1.88. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same quarter in the previous year, the business earned ($1.43) EPS. The business's revenue was up 71.6% compared to the same quarter last year. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 9,973 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $423,054.66. Following the transaction, the chief executive officer now directly owns 180,890 shares of the company's stock, valued at approximately $7,673,353.80. This trade represents a 5.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Julianne Bruno sold 1,198 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the transaction, the chief operating officer now directly owns 8,263 shares in the company, valued at $350,516.46. This trade represents a 12.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,021 shares of company stock valued at $594,771 in the last 90 days. Corporate insiders own 4.30% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.